Effectiveness of Cabergoline to Reduce the Risk of Progression from Prediabetes to Type 2 Diabetes and Control of Insulin Resistance

Introduction: Type 2 diabetes has become prevalent in recent decades due to sedentary life style and unhealthy diet. Although many new medicines have developed, this disease is still uncontrolled. Considering the high prevalence of obesity and metabolic syndrome, we evaluated the efficacy of dopamine agonist Cabergolin to reduce the risk of progression from prediabetes to type 2 diabetes. It targets the central pathway of glucose metabolism and has low complication compared to Bromocriptine.Materials & Methods: In this study 80 patients were treated with Cabergoline for 16 weeks. In the first 4 weeks, patients received 0.25 mg Cabergoline orally twice weekly before sleeping. Then the dosage was increased to 0.5 mg twice weekly and it was continued for 12 weeks.Results: Cabergoline could significantly reduce the values of FPG and 2h-PG in OGTT, Hb-A1c,Cholesterol, LDL, 2h-Insulin, HOMA-IR, ISI Matsuda, ISI Cederholm and QUICKI tests(p<0.05).It did not have any significant effects on weight, BMI, waist circumference and parameters like Fasting Insulin, HDL, Atherogenic Factor (LDL / HDL) and HOMA-β compared to placebo (p> 0.05). Although in some of these parameters, such as HDL, Fasting Insulin and Atherogenic Factor, the changes trend is in the favor of the corrective effects (p< 0.05).Conclusion: Cabergoline can improve the biochemical factors of the glucose metabolism (FPG & 2h-PG in OGTT test, Hb-A1c, Cholesterol, LDL, 2H-Insulin, HOMA-IR, ISI Matsuda, ISI, Cederholm and QUICKI) and in some parameters despite of no significant change, it prevents exacerbation of the disease and trends correction of that parameters.